All In Biotech

Guides

How to search Drugs@FDA: approval history, labels and letters

How to search Drugs@FDA step by step: find a drug's application, read its approval history, and open approval letters, FDA reviews and every label version.

By the All In Biotech editorial team · Published November 18, 2026 · 6 min read

To search Drugs@FDA, go to FDA's Drugs@FDA page, type a brand name, active ingredient or application number, and open the application you want. Its "Approval Date(s) and History, Letters, Labels, Reviews" section lists every approval in date order, with links to the approval letter, FDA's review documents and the label approved at each step.

The steps below explain what each screen shows and how to read it.

What Drugs@FDA covers

Drugs@FDA holds most drug products approved since 1939. For products approved from 1998 onward, it usually links the documents behind each approval. It covers prescription and over-the-counter drugs, brand-name and generic, and therapeutic biologics such as monoclonal antibodies that are reviewed by FDA's Center for Drug Evaluation and Research (CDER).

It does not cover most vaccines, blood products or cell and gene therapies, which are approved by the Center for Biologics Evaluation and Research (CBER). It also does not cover dietary supplements, animal drugs or drugs approved only outside the US.

The database is organized by application:

  • NDA (New Drug Application): most brand-name small-molecule drugs.
  • BLA (Biologics License Application): biologics such as antibodies and, since 2020, products like insulin that FDA transitioned from NDAs.
  • ANDA (Abbreviated New Drug Application): generic versions of NDA drugs.

Drugs@FDA holds about 23,000 ANDAs. This site's catalog leaves generics out and holds the 5,899 brand-name applications (5,412 NDAs and 487 BLAs) in the November 2026 download. For more on the application types, see NDA vs BLA vs ANDA.

Step by step: find a drug's approval history

  1. Search. On the Drugs@FDA home page, enter the brand name (for example Ozempic), the active ingredient (semaglutide) or the application number (209637). Ingredient searches return brands and generics together, which can be a long list.
  2. Pick the application. Results group products by application. One drug name can appear under several applications, because a company can file a new dosage form or strength as a separate NDA. Semaglutide is a good example: the Ozempic injection is NDA 209637, the oral tablets first approved in 2019 are NDA 213051 (Drugs@FDA lists Ozempic and Rybelsus products under it), and Wegovy has its own NDAs. Search by active ingredient to see them all.
  3. Read the product table. The application page lists each product's strength, dosage form, route, marketing status (prescription, over-the-counter or discontinued) and, for NDA products, fields such as the therapeutic equivalence code and whether it is a reference listed drug.
  4. Open the approval history. Expand "Approval Date(s) and History, Letters, Labels, Reviews". This table is the core of Drugs@FDA.
  5. Open the documents. Each row links what FDA has posted for that action: the letter, the label and, for many original approvals and major supplements, the review.

How to read the approval history table

Each row is one FDA action on the application. The columns that matter most:

ColumnWhat it means
Action dateThe date FDA acted
SubmissionORIG-1 is the original application. SUPPL-n is the nth supplement
Action typeUsually Approval. Generic applications can also show Tentative Approval
Submission classificationFor an original, the chemical type (Type 1 is a new molecular entity). For a supplement, the kind of change, such as a new indication (efficacy), labeling or manufacturing (CMC)
Review priority and orphan statusPriority or standard review, and whether orphan status applies, where recorded
Letters, Reviews, LabelsLinks to the documents FDA posted for that action

Column names have shifted slightly over the years, but these fields are present for most modern records.

The original approval date is the ORIG-1 row. Every later row is a change to the approved application. Efficacy supplements are the ones that add a new use, a new patient population or a new dosing regimen, so they are the rows to read if you want to know how a drug's approved uses grew over time.

Keytruda (pembrolizumab, BLA 125514) shows how long this table can get. It was first approved on September 4, 2014, and as of November 2026 its Drugs@FDA record holds 110 approved uses counting the original approval and efficacy supplements.

Approval letters

The approval letter is FDA's formal notice to the company. It states what was approved, lists any postmarketing requirements and commitments (studies the company must or agreed to run after approval), and notes any Risk Evaluation and Mitigation Strategy (REMS). For accelerated approvals, the letter names the confirmatory trials the company must complete.

Letters for older products may be missing or posted as scanned images. For recent approvals the letter is usually the first document posted, but timing varies.

Review documents

FDA's reviews, sometimes posted as an "approval package" or multi-discipline review, are where the agency explains its reasoning. They can include medical, statistical, clinical pharmacology, chemistry and manufacturing reviews, along with summaries by the division and office directors.

They are long, and parts are redacted to protect trade secrets and confidential commercial information. They are posted for most novel approvals and major supplements, but often weeks or months after the action date. If you are researching a recent approval and the "Review" link is missing, check again later.

Labels over time

Every label version FDA approved is linked from the history table, so you can see how a drug's indications, warnings and dosing changed. For the label as it is today, use DailyMed, which carries the most recent version the company submitted. The two can briefly differ after a new approval.

What Drugs@FDA does not tell you

  • Rejections. Drugs@FDA records approvals. When FDA does not approve an application it issues a complete response letter (CRL). In 2025 FDA began publishing CRLs in a collection on openFDA, including some for applications that were never approved. Before that, most CRLs were only public if the company disclosed them.
  • Pending applications. There is no public list of applications under review. Target action dates come from company announcements; see what is a PDUFA date.
  • Patents and exclusivity. These are in the Orange Book for NDA drugs and the Purple Book for biologics.
  • Expedited program status. Breakthrough therapy and accelerated approval status is shown on separate FDA lists. This site combines them on the designations page.
  • Whether a drug is actually sold. "Prescription" marketing status means the product is listed as marketed, but shortages and quiet discontinuations happen. Of the 5,899 brand-name applications in this site's catalog, 3,248 have at least one product still listed as marketed.

Tips for faster searches

  • Search by active ingredient when a brand name returns nothing. Brand names change, and some products are listed under the ingredient alone.
  • Use the application number when you have it. It is the only identifier that points to exactly one record.
  • For novel drugs, FDA's Novel Drug Approvals pages list each year's new molecular entities and new therapeutic biologics with links back to Drugs@FDA. As of November 17, 2026, CDER had approved 53 novel drugs in 2026, after 46 in 2025.
  • For bulk work, FDA publishes the database as Drugs@FDA data files, and openFDA offers the same data through an API. Both are free.

Using Drugs@FDA with other sources

Drugs@FDA answers "what did FDA approve, and when?" Pair it with ClinicalTrials.gov for the trials behind an approval, with the label on DailyMed for current prescribing information, and with FAERS for postmarketing safety reports. The overview of free drug databases explains which source to use for which question, and this site's drug catalog puts them side by side for each brand-name drug.

Frequently asked questions

What is Drugs@FDA?
Drugs@FDA is FDA's public database of drugs approved by its Center for Drug Evaluation and Research, with approval histories and, for most products approved since 1998, letters, reviews and labels.
How do I find the date a drug was approved?
Search Drugs@FDA by brand name or ingredient, open the application, and look for the original approval (ORIG-1) in the approval history table.
Why can't I find a vaccine in Drugs@FDA?
Most vaccines, blood products and cell and gene therapies are approved by FDA's Center for Biologics Evaluation and Research and are listed on CBER's own pages instead.
Does Drugs@FDA show rejected applications?
It lists approvals. Since 2025 FDA has also published many complete response letters, which explain why an application was not approved, through openFDA.

For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.

Keep reading